

RADIATION ONCOLOGY QUALITY ASSURANCE COMMITTEE

CHELSEA HOTEL, TORONTO, ON

ROOM: CARLYLE

FRIDAY APRIL 28TH, 2022, 1:00 PM – 4:00 PM EST

RADIATION ONCOLOGIST CO-CHAIR: ALAN NICHOL

MEDICAL PHYSICIST CO-CHAIR: OREST OSTAPIAK

SENIOR INVESTIGATOR: WENDY PARULEKAR

CME Credits:

Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.

Learning Objectives:

- To list the CCTG led trials and the quality assurance infrastructure
- To identify best practices and quality initiatives in radiotherapy delivery as they relate to clinical trial conduct
- To provide input and guidance for the CCTG generic protocol regarding radiotherapy administration and quality assurance

1:00 pm Welcome A. Nichol

1:05 pm Review of ROQAC Terms of Reference

1:35 pm CCTG Ongoing Trials Previously Presented

Accrual Updates:

Phase II randomized study comparing HDR vs LDR monotherapy in localized prostate cancer. **PR.19**

Phase 3 Trial of Local Ablative Therapy or Not for Hormone Sensitive Oligometastatic Prostate Cancer. **PR.20**

TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer. **MA.39**

A Phase III Trial of Stereotactic Radiosurgery Compared with Whole Brain Radiotherapy (WBRT) for 5-15 Brain Metastases. **CE.7**

Randomized Phase II Study of Cisplatin + RT vs Durvalumab + RT followed by Maintenance Durvalumab vs Durvalumab plus RT followed by Maintenance Tremelimumab and Durvalumab in Intermediate Risk HPV-Positive Locoregionally Advanced Oropharyngeal Squamous Cell Ca (LA-OSCC). **HN.9**

EVADER: Phase II trial of Elective Volume Adjusted De-Escalation RT in Patients with low-risk HPV-related oropharyngeal squamous cell ca. **HN.10**



SPECT-CT Guided ELEctive Contralateral Neck Treatment in Lateralized Oropharynx Cancer (SELECT): A Phase III Randomized Controlled Trial. **HN.11**

CCTG Approved Trials Not Activated

Optimizing Head and Neck Tumour And Symptom Control in Patients Unable to Tolerate Curative Intent RT: A Phase III Trial Comparing Stereotactic Body Radiation Therapy (SBRT) to Standard Palliative Radiation Treatment (ON-TASC Study). **HN.13**

CIHR Re-submission Spring 2023

1:55 pm

A Randomized Phase 3 Trial Comparing Stereotactic Body Radiotherapy to Conventional Palliative Radiotherapy for Painful Non-Spine Bone Metastases.

SC.29

CIHR Initial Submission Spring 2023

A. Sahgal

2:05 pm

Androgen Suppression Combined with Elective Nodal Irradiation and Dose Escalated Prostate Treatment: A Non-Inferiority, Phase III Randomized Controlled Trial of Stereotactic Body Radiation Therapy versus Brachytherapy Boost (ASCENDE-SBRT). **PR.24**

A. Loblaw

Other Business

2:15 pm

Review of Guidance on the Use of Common Nomenclature in Canadian Radiation Treatment Programs

A. Nichol

Meeting Adjourned

